Taiwan Expected To Approve Soon Nation's First Weight-loss Drug
This article was originally published in PharmAsia News
Executive Summary
Taiwan's Bureau of Pharmaceutical Affairs is expected to give the go-ahead to GlaxoSmithKline to market its Alli (orlistat) drug to people seeking to lose weight in Taiwain. The BPA has reviewed safety aspects of the drug, but an official warns potential patients need to remember Alliis a drug and should be handled with precaution. The official suggested GSK might have to provide an easy-to-read leaflet describing side effects of the drug and a requirement pharmacists explain its use. (Click here for more